Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prefusion F protein + Advax
- Development stage
- Preclinical
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Prefusion F protein + Advax is a preclinical-stage recombinant protein vaccine candidate developed by Vaxine for the prevention of respiratory syncytial virus (RSV) infection and associated conditions such as bronchiolitis and pneumonia. The vaccine consists of a stabilized RSV prefusion F protein antigen, which is the viral surface glycoprotein in its prefusion conformation responsible for mediating viral fusion and host-cell entry. It is formulated with Vaxine's proprietary Advax adjuvant system, specifically Advax-SM, which comprises delta inulin polysaccharide combined with a TLR9 agonist (CpG oligodeoxynucleotides). This combination is designed to induce potent neutralizing antibodies and a balanced Th1/Th2 immune response, providing protective immunity while avoiding the Th2-skewed lung pathology historically associated with some RSV vaccine candidates.
- Other names
- prefusion F + Advax RSV vaccineRSV Vaccine (prefusion F + Advax)
02
Targets
TLR9 (Toll-like receptor 9)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on prefusion F protein + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prefusion F protein + Advax.